1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFollow-on funding for Phase I awardees advancing digital technologies with potential heritage preservation applications.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. small businesses with prior Phase I award. Confirm the full requirements in the official notice before applying.
The current listing shows up to $2.15M. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 8, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
SBIR Phase II — NIH (PHS Omnibus) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Small Business Transition Grant for New Entrepreneurs (SBIR) — R43 Phase I is a grant from the National Institutes of Health (NIH) that funds early-stage scientific innovation by small businesses aiming to bring biomedical breakthroughs to the commercial marketplace. The Phase I award supports feasibility research, evaluating technical merit and commercial potential of proposed innovations. Eligible applicants are U.S. small business concerns, particularly new entrepreneurs, applying under PAR-24-131. Awards cover up to approximately $306,872 in total costs for Phase I. The most recent deadline is September 5, 2026.
NIH SBIR/STTR Parent SBIR (R43/R44) Clinical Trial Not Allowed (PA-24-245) is sponsored by National Institutes of Health (NIH). The NIH SBIR program supports small businesses developing innovative technologies that address health-related challenges through Phase I and Phase II funding, focusing on establishing technical feasibility, research and development, and advancing toward commercialization.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article